Trial record 19 of 25 for:    "Abdominal Abscess"

Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

This study has been withdrawn prior to enrollment.
Information provided by:
Pfizer Identifier:
First received: April 17, 2007
Last updated: April 21, 2011
Last verified: April 2011

The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Condition Intervention Phase
Abscess, Intra-Abdominal
Wound Infections
Drug: CP-75385-02 Cefoperazone/sulbactam
Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Enrollment: 0
Study Start Date: May 2007

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patient of age 18 years or older.
  • Patient with intraabdominal/hepatobiliary infection.?

Exclusion Criteria:

  • Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00463762

Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided Identifier: NCT00463762     History of Changes
Other Study ID Numbers: A1891004
Study First Received: April 17, 2007
Last Updated: April 21, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Abdominal Abscess
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Infective Agents, Urinary
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Renal Agents
Therapeutic Uses processed this record on March 26, 2015